Lemme GLP-1 Daily fraud class action dismissed without prejudice in New York
The Lemme GLP-1 Daily case ended by agreement before any judge ruled, leaving the marketing claims at the center of the suit unresolved for consumers.
A federal class action against the supplement company Lemme Inc. ended on April 16, 2025, when the parties filed a stipulation of voluntary dismissal without prejudice in the U.S. District Court for the Southern District of New York [1]. No judge ruled on the allegations, so the claims were never tested in court [1].
The case, Robins v. Lemme Inc., No. 1:25-cv-01938, was filed on March 9, 2025, before Judge Margaret M. Garnett [1]. The docket lists the nature of the suit as "Torts - Personal Property - Other Fraud," brought under diversity jurisdiction [1]. The plaintiff is Christina Robins; the defendant is Lemme Inc. [1]. The dispute concerned Lemme GLP-1 Daily, a supplement, and claims that it boosted GLP-1 and reduced hunger.
The case moved quickly. Lemme waived formal service on March 11, 2025, with an answer due May 12, 2025 [1]. On April 8, 2025, the company filed a motion to dismiss, a supporting memorandum of law and a corporate disclosure statement [1]. That same month, a joint request pushed the initial pretrial conference from May 15, 2025 to July 31, 2025, with the parties' pre-conference submission moved to July 24, 2025 [1].
Eight days after the motion to dismiss, on April 16, 2025, the parties filed the stipulation of voluntary dismissal under Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure [1]. An earlier version filed April 15 was returned by the clerk's office as deficient because it was not signed by all parties who had appeared; the corrected filing followed the next day [1]. The docket records the case as terminated April 16, 2025 [1].
Because the dismissal came by stipulation rather than by court order, no judge weighed the fraud allegations. The docket does not say whether a settlement was reached or whether any payment was made, and no terms have been disclosed [1]. A dismissal "without prejudice" means the plaintiff can bring the claims again; it is not a ruling that the allegations were true or false [1].
Why it matters for patients
People weighing supplements marketed around GLP-1 drugs such as Ozempic and Wegovy (semaglutide) got no answer from this case. The central question — whether the marketing claims for Lemme GLP-1 Daily held up — was never decided by a court [1]. The dismissal also does not clear the product: a voluntary dismissal without prejudice leaves the allegations legally unresolved in either direction [1].
What the record does show is narrower. A fraud case was filed, the company moved to dismiss it, and the parties ended it by agreement about five weeks after it started [1]. Court records do not say why, and no filing in the docket explains the parties' reasons [1].
What happens next
The federal case is closed [1]. A separate action filed by the same plaintiff in Los Angeles Superior Court in February 2025 remains a distinct matter; no ruling in it has been reported. Whether the plaintiff refiles in New York has not been reported. Nothing in the docket indicates whether Lemme changed its marketing for Lemme GLP-1 Daily [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.